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Abstract: An improved understanding of renal cell carcinoma (RCC) biology has translated 
into major advances in the treatment of patients with metastatic RCC in recent years. Clinical 
and pathologic criteria can be used to identify RCC patients with poor prognoses. Such patients, 
however, are often excluded from the cancer clinical trials that guide treatment recommenda-
tions. This article reviews available information on the management of patients with metastatic 
RCC and poor risk features, focusing on the role of vascular endothelial growth factor (VEGF) 
pathway and mammalian target of rapamycin (mTOR) inhibitors. While patients with poor risk 
features have a more guarded outcome, treatment with temsirolimus has produced meaningful 
improvements in overall survival for this population. Definitive phase III trial data are lacking 
for the VEGF pathway inhibitors in patients with poor prognostic features. However, available 
data suggest that such patients tolerate VEGF pathway blockade reasonably well and are likely 
to achieve some benefit relative to treatment with interferon. Ongoing translational research 
efforts may help to define novel treatment approaches specific for patients with metastatic RCC 
and poor prognostic features.
Keywords:  renal cell carcinoma, prognostic criteria, vascular endothelial growth factor (VEGF)-
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Introduction
Renal cell carcinoma (RCC) is predicted to account for 58,000 new cases and nearly 
13,000 deaths in 2009.1 For patients who present with early stage disease the 5-year 
survival is estimated at 66%. However, up to 40% of those who present with localized 
disease will develop metastases,2,3 and the 5-year survival in metastatic disease is still 
less than 20%.4,5 For patients with poor prognostic features, as defined by the Memo-
rial Sloan Kettering Cancer Center (MSKCC) staging system, the outlook can be even 
more grim with median survival of 4 months and few patients surviving 1 year.6
In recent years an improved understanding of RCC tumor biology has translated 
into major advancements in the treatment of patients with metastatic RCC. Several 
new molecularly targeted agents have been identified that have led to significant 
improvements in progression-free survival and a general increase in overall survival. 
These include inhibitors of the vascular endothelial growth factor (VEGF) pathway 
(eg, sunitinib, sorafenib, and bevacizumab), and inhibitors of the mammalian target 
of rapamycin (mTor) pathway (eg, temsirolimus and everolimus).
Cancer clinical trials are often conducted in well selected populations with strict 
inclusion criteria that exclude patients with poor performance status or significant 
co-morbidities. For example, only one of the pivotal trials that resulted in Food and Cancer Management and Research 2010:2 124
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Table 1 Phase iii trials of targeted therapy in advanced renal cell carcinoma
Agent  Trial  Size  Percent  
poor risk
Overall PFS  
(95% CI)
Overall response  
rate (95% CI)
Overall disease  
control rate
Sunitinib Motzer 200737 N = 750 6.4% 11 months  
(10–12)
31% (26–36) 79%
Sorafenib escudier 200757 N = 903 0% 5.5 months 10% (7–13) 62% (57–66)
Temsirolimus Hudes 200735 N = 626 74% 5.5 months  
(3.9–7.0)
8.6% (4.8–12.4) 32.1% (25.7–38.4)
everolimus Motzer 200836 N = 410 15% 4.0 months  
(3.7–5.5)
1% 64%
Bevacizumab/iFN escudier 200738 N = 649 9% 10.2 months 31% 77%
Bevacizumab/iFN Rini 200839 N = 732 10% 8.5 months  
(7.5–9.7)
25.5% (20.9–30.6)
Drug Administration (FDA) approval for the agents discussed 
above included a substantial number of patients with poor 
prognostic features (Table 1). For this reason, the optimal 
approach to the management of patients with metastatic RCC 
and poor risk features may be difficult to determine from trial 
reports. In this article, we review the available information 
on management of patients with RCC and poor risk features, 
focusing on the role of VEGF-pathway and mTOR inhibitors 
in this population.
Defining prognostic criteria
Clinical prognostic factors
Prognostic criteria can be used in designing and stratifying 
participants in clinical trials, counseling patients, and direct-
ing therapy. Several investigators have attempted to define 
prognostic criteria for patients with metastatic RCC in order 
to guide clinical decision making. Table 2 summarizes the 
most commonly applied prognostic models.
The Memorial Sloan Kettering Cancer Center (MSKCC) 
criteria, first published in 1999, defined pretreatment clini-
cal features that were predictive of survival in patients with 
metastatic RCC who had not received prior therapy. Five 
prognostic factors, including hemoglobin, lactate dehydro-
genase, corrected serum calcium, prior nephrectomy, and 
Karnofsky performance status, were identified by multivari-
ate analysis as having independent prognostic implications 
with regard to overall survival.6
Based on these criteria, patients were stratified into 3 risk 
categories, favorable (no risk factors), intermediate (1 or 2 
risk factors), and poor (3 or more risk factors), according 
to the number of high-risk features present. The prognostic 
criteria were validated using an internal bootstrap technique 
in which subpopulations of the parent sample group were 
tested against the prognostic model.6 Median survival in the 
favorable-risk group was 20 months, in the intermediate-risk 
group 10 months, and in the poor-risk group 4 months. These 
prognostic criteria became a standard by which participants 
with RCC are assessed and stratified prior to enrollment in 
clinical trials.
Following results of 2 phase III trials demonstrating 
a survival benefit for cytoreductive nephrectomy prior to 
interferon-α (IFN-α),7,8 debulking nephrectomy followed 
by IFN became a standard approach for patients presenting 
with stage IV disease. Concurrent with this, the MSKCC 
criteria were modified based on a new prognostic model 
in which time to treatment with IFN replaced the presence 
or absence of prior nephrectomy.4 This prognostic model 
included Karnofsky performance status, hemoglobin, cor-
rected serum calcium, lactate dehydrogenase, and time from 
initial diagnosis to treatment with IFN within or more than 
one year. The MSKCC version 2 criteria were also established 
by multivariate analysis and validated by internal bootstrap 
technique. Median survival in the favorable risk group was 
30 months, in the intermediate risk group 14 months, and 
in the poor risk group 5 months.4 The MSKCC prognostic 
criteria version 2 have been recognized as an appropriate 
model for risk stratification in phase III trials utilizing IFN 
as the control arm and in single-arm phase II trials evaluating 
progression-free survival.
The MSKCC prognostic criteria version 2 were exter-
nally validated in an independent sample population with 
survival as the primary endpoint by investigators from the 
Cleveland Clinic.9 Median survival times were 28.6, 14.6 
and 4.5 months in the favorable, intermediate, and poor risk 
groups, respectively (P  0.0001) (Figure 1). Four of the five 
previously identified risk factors, hemoglobin, corrected serum 
calcium, lactate dehydrogenase, and time from initial diag-
nosis to treatment with IFN, were found to be independently Cancer Management and Research 2010:2 125
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predictive of survival. Performance status was not found to 
be a significant predictive factor; however, all participants 
involved in this assessment had been subjects of clinical trials 
that required Easter Cooperative Oncology Group (ECOG) 
performance status of 0 or 1 for enrollment. Therefore, all 
participants would have had favorable performance status by 
MSKCC criteria. This study also identified prior radiotherapy 
and the presence of liver, lung, or retroperitoneal nodal metas-
tasis as independent poor risk factors.9
Negrier et al developed a prognostic model for patients 
being treated with interleukin-2 (IL-2) and IFN cytokine 
therapies. Four independent factors, including presence 
of liver metastases, duration from primary tumor to 
metastasis less than 1 year, more than 1 metastatic site, 
and neutrophilia, were predictive of rapid progression on 
cytokine therapy. Patients who demonstrated 3 or more of 
these factors had an 80% probability of rapid progression 
despite therapy.10
It should be noted that the clinical prognostic models 
described above have focused on survival as the primary 
endpoint following IFN and/or low-dose IL-2 as the therapy. 
While this has aided in trial design and balancing treatment 
arms, the extent to which these models are valid in trials that 
look at progression-free survival as the primary endpoint 
and involve agents other than low dose cytokines is not fully 
established.
Newer prognostic models may be needed in the era of 
anti-angiogenic and targeted therapy. Choueiri et al identi-
fied 5 clinical factors by multivariate analysis that predicted 
for progression-free survival in patients treated with the 
antiangiogenesis agents sunitinib, sorafenib, axitinib, or beva-
cizumab.11 These included time from diagnosis to treatment 
less than 2 years, neutrophil count, platelet count, ECOG 
performance status, and corrected serum calcium. When 
stratified into 3 groups, zero or 1 factor, 2 factors, versus 3 
or more factors, the median progression-free survivals were 
20.1, 13.0, and 3.9 months, respectively.
Recently Heng and colleagues described a more extensive 
prognostic risk model for patients treated with VEGF-targeted 
therapy.12 They studied 645 patients who had not received prior 
anti-VEGF therapy and were treated with sunitinib, sorafenib, 
or bevacizumab plus IFN. By Cox proportional hazard model, 
6 independent predictors of poor survival were identified 
including anemia, hypercalcemia, Karnofsky performance 
status less than 80%, time from initial diagnosis to initiation 
of therapy less than 1 year, neutrophilia, and thrombocytosis. 
Patients were categorized as favorable risk (no adverse fac-
tors), intermediate risk (1 to 2 adverse factors), or poor risk 
(3 to 6 adverse factors). At the time of publication, median 
overall survival was not reached in the favorable-risk group, 
27 months in the intermediate-risk group, and 8.8 months 
in the poor-risk group.12 The model was internally assessed 
Table 2 Clinical prognostic criteria
Memorial Sloan Kettering Motzer 19996 Corrected serum calcium
Cancer Center Prognostic Hemoglobin
Criteria – version 1 Karnofsky performance status
Lactate dehydrogenase
Prior nephrectomy
Memorial Sloan Kettering Motzer 20024 Corrected serum calcium
Cancer Center Prognostic  Hemoglobin
Criteria – version 2 Karnofsky performance status
Lactate dehydrogenase
Time from initial diagnosis to treatment 
with iFN-α
Cleveland Clinic Mekhail 20059 Corrected serum calcium
Hemoglobin
Lactate dehydrogenase
Presence of liver, lung, or retroperitoneal nodal   
metastasis
Prior radiotherapy
Time from initial diagnosis to treatment with  
iFN-α
French Prognostic Criteria escudier 200219 Alkaline phosphatase
Corrected serum calcium
Lactate dehydrogenase
Number of metastatic sites
    Time from nephrectomy to metastatic diseaseCancer Management and Research 2010:2 126
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by bootstrap validation, and external validation is ongoing. 
Nonclear cell and sarcomatoid histologies as well elevated 
lactate dehydrogenase (LDH) and nephrectomy status were 
also shown to be indicators of poor prognosis but were not 
identified as independent prognostic features and thus were 
not included in the model. Similar analyses restricted to 
patients treated with mTOR inhibitors have yet to be per-
formed.
Pathologic and molecular  
prognostic factors
Pathologic features that have been proposed as prognostic in 
RCC include nuclear grade, histologic subtype, and molecu-
lar biomarkers (Table 3). While nuclear grade has been rec-
ognized as an independent predictor of survival in early stage 
disease,13–15 it has not been shown to correlate with survival 
in the metastatic setting.9,16 Patard et al presented an analysis 
of 4000 patients with stage I-III RCC showing differences in 
survival based on histologic subtype.14 In this study estimated 
5-year survival rates for those with clear cell, papillary, and 
chromophobe tumors were 64%, 70%, and 84% respectively 
(P  0.001).14 Sarcomatoid features within the tumor have 
also been associated with poor prognosis.16,17 Sarcomatoid 
features can be present in all histologic subtypes, and median 
survival for patients presenting with such features ranges 
from 2 to 9 months.17–20
Prognostic molecular biomarkers have been identified by 
both DNA microarray and tissue array techniques. Using tissue 
array data from 150 metastatic clear cell renal cell tumors, Kim 
et al isolated CAIX, p53, PTEN, and vimentin as independent 
prognostic factors for survival in metastatic RCC.21 Increased 
immunohistochemical staining of p53 and vimentin predicted 
for poor survival, while increased staining with CAIX and 
PTEN were associated with more favorable outcomes. Leibov-
ich et al found that while low CAIX expression in nephrectomy 
specimens correlated with worse survival, this observation was 
not seen after adjusting for nuclear grade or tumor necrosis, 
and concluded that CAIX expression as a predictive marker 
required additional investigation.22 Increased CAIX tumor 
expression has also been found to be an independent predictor 
of prolonged survival in patients treated with IL-2.23–25
Mutations, deletions, and/or hypermethylation in the VHL 
gene have been identified in 60% of patients with clear cell 
RCC, but results from studies assessing whether VHL loss 
correlates with survival have been variable.26–28 PTEN loss has 
been associated with AKT activation, and studies have shown 
that pAKT tumor expression correlates with worse survival.29 
Tumor expression of the insulin-like growth factor-II mRNA 
binding protein, IMP3, has been linked to poor outcome 
perhaps due to its association with poor prognostic features 
including tumor necrosis and sarcomatoid differentiation.30 
Hoffmann et al found a 42% increased risk of death 
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Figure 1 Survival curves from MSKCC and Cleveland Clinic criteria by prognostic category. Adapted with permission from Bukowski RM. Prognostic factors for survival in 
metastatic renal cell carcinoma: update 2008. Cancer. 2009;115(10 Suppl):2273–2281.59 Copyright © 2009 John wiley & Sons, inc.Cancer Management and Research 2010:2 127
Management of metastatic renal cell carcinoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
from RCC in patients whose tumor IMP3 expression was 
positive.30 Finally, expression of B7H1 and B7H4 in renal 
cancers (molecules that are associated with tumor induced 
immune suppression) has been associated with poor sur-
vival.31,32 While research focused on tissue based prognostic 
biomarkers in RCC potentially provides a means of identify-
ing novel therapeutic targets and predictors of therapeutic 
response, the clinical parameters outlined above remain the 
standard approach for risk stratification in ongoing clinical 
trials and treatment selection in clinical practice.
Treatment of RCC in patients  
with poor prognostic features
iFN-α in the treatment of patients  
with poor prognostic features
The MSKCC prognostic criteria were developed in patients 
receiving IFN in the first-line setting (Table 2).4 Outcome 
of patients in the poor-risk group was disappointing. 
Median overall survival following treatment with IFN 
was 4.9 months, 1-year survival was 20%, and 12 months 
progression-free survival was only 10%. Other studies 
have suggested that even intermediate-risk patients (as 
defined by the French criteria [Table 2]) do not benefit from 
cytokine-based treatments.33 This work has led to the rec-
ommendation by many that angiogenesis inhibitors and tar-
geted therapies should be the preferred treatment approach 
in patients with intermediate-and poor-risk RCC.
mTor inhibitors in the treatment  
of patients with poor prognostic features
Temsirolimus, a mammalian target of rapamycin (mTor) kinase 
inhibitor, was first evaluated in patients with metastatic RCC 
in a randomized phase II study.34 The primary endpoint was 
objective tumor response. In this study participants were retro-
spectively classified according to MSKCC prognostic criteria. 
When compared to treatment with IFN,4 median survival in 
temsirolimus-treated patients was 1.6- to 1.7-fold longer for 
populations with intermediate and poor prognosis. This advan-
tage was not observed in the favorable prognosis population, 
raising the suggestion that mTor inhibition was particularly 
active in patients with poor prognostic features or that mTor 
activity was associated with more aggressive disease.34
Recognizing the limitations of treatment with IFN in the 
poor risk setting, Hudes et al examined the effect of treat-
ing with temsirolimus or combination temsirolimus plus 
IFN compared to standard IFN in poor prognosis patients.35 
Inclusion criteria consisted of at least 3 of 6 predictors of 
short-term survival as defined by the Cleveland Clinic.9 
Seventy-four percent of patients were classified as poor risk 
by the more restrictive MSKCC model with the remainder 
being considered of intermediate risk. Eligibility criteria 
also included Karnofsky performance status of 60 or more, 
no prior systemic therapy, and adequate bone marrow, renal, 
and hepatic function.
Results demonstrated improved overall survival and 
progression-free survival in participants who received temsi-
rolimus alone, median overall survival 10.9 months versus 7.3 
months with IFN alone (P  0.0001). Median progression-free 
survivals were 1.9 months for IFN, 5.5 months for temsirolimus, 
and 4.7 months for the combination. There were no significant 
differences in objective response rates: 4.8% for IFN, 8.6% for 
temsirolimus, and 8.1% for the combination. However, disease 
control rate, including stable disease, was significantly higher 
in the temsirolimus arm (32.1%) compared to the IFN arm 
(15.5%, P  0.001). There were also fewer patients with grade 3 
and 4 toxicities in the temsirolimus arm (P = 0.02).35 According 
to subgroup analyses, the benefit of temsirolimus relative to IFN 
was more pronounced in patients with factors that have been 
identified as indicators of poor prognosis, eg, high LDH, low 
Karnofsky performance status, non-clear cell histology, and 
no prior nephrectomy. Based on these results, temsirolimus 
was granted FDA approval for treatment of patients with 
advanced RCC in 2007 and is now considered a standard 
therapy for patients with poor risk features.
Everolimus was approved for treatment of metastatic 
RCC in the second-line setting based on results of a phase III 
placebo-controlled trial published in 2008. All participants 
in this study had disease that progressed following sorafenib 
and/or sunitinib therapy.36 This study was stopped early after 
results of the second interim analysis showed a significant 
Table 3 Biomarkers of prognosis in renal cell carcinoma
Histology
  Clear cell
  Chromophobe
  Papillary
  Sarcomatoid
Molecular biomarkers
  CAiX tumor expression
  p53 tumor expression
  PTeN tumor expression
  vimentin tumor expression
  pAKT tumor expression
  iMP3 tumor expression
  B7H1/B7H4 tumor expression
Genetic biomarkers
  vHL mutation, deletion, and/or hypermethylationCancer Management and Research 2010:2 128
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delay in progression-free survival from 1.9 months in the 
placebo arm to 3.9 months in the everolimus arm. Although 
this trial enrolled patients who had failed prior VEGF targeted 
therapy (a group for which no prognostic modeling exists) 
the majority of patients were deemed to be of favorable or 
intermediate MSKCC risk based on pre-treatment variables. 
Only 15% of patients were considered poor risk.36 Thus the 
value of everolimus in previously untreated patients with 
poor risk features remains to be established.
veGF pathway inhibitors in the treatment 
of patients with poor prognostic features
Although no trials with vascular endothelial growth factor 
(VEGF) pathway inhibitors have been restricted to patients 
with predominantly poor prognostic features, some information 
regarding the activity of these agents in this population can be 
gleaned from looking at subsets of patients with poor prognostic 
features. The phase III trials that confirmed the benefit of suni-
tinib, bevacizumab + IFN, and pazaponib each enrolled a small 
proportion of patients with poor prognostic features.37–40
Sunitinib was compared to IFN in the first-line setting in 
a randomized phase III trial in which the overall response rate 
was 31% and median progression-free survival 11 months 
for sunitinib compared to a response rate of 6% and median 
progression-free survival of 5 months with IFN, P  0.001.37 
Participants in the phase III sunitinib trial were stratified 
according to LDH level, ECOG performance status, and 
whether or not they had previously undergone nephrectomy.37 
Sunitinib treatment was assessed by Cox proportional-hazard 
model across a series of factors previously identified as por-
tending poor prognosis including previous nephrectomy, age, 
sex, ECOG performance status, LDH level, time since diagno-
sis, hemoglobin level, and corrected serum calcium level, and 
demonstrated improved progression-free survival across each 
subgroup. Overall survival assessed in a follow-up of this study 
similarly showed significant benefit from sunitinib treatment 
among patients with poor prognostic features (Table 4).41
Participants in the phase III sunitinib trial were also assessed 
according to MSKCC prognostic criteria version 2,4 and in all 
risk groups, favorable, intermediate, and poor, sunitinib showed 
improved progression-free survival as compared to IFN. Only 
48 of the 750 (6.4%) participants enrolled in the trial, however, 
met criteria for poor risk characterization. Median progression-
free survival for poor-risk patients in the sunitinib group was 
4 months compared to 1 month in the IFN group. In the follow-
up analysis median overall survival was 5.3 months in poor risk 
patients treated with sunitinib (95% confidence interval [CI], 
4.2 to 10.0) compared to 4.0 months in those treated with IFN 
(95% CI, 2.7 to 7.2).41 Taken together, these data indicate that 
sunitinib has efficacy in patients with poor prognostic features 
comparable to that observed for the trial as a whole.
In an effort to expand the available data and apply it to an 
unselected “real-world” population that would be more con-
sistent with community practice Heng et al performed a retro-
spective analysis comparing sunitinib with IFN that included 
a large proportion of patients with poor risk features.12 For 
patients with poor risk features median overall survival 
on sunitinib was 10.7 months compared to 4.1 months on 
IFN, P = 0.0329. Median progression-free survival in the 
patients included in this analysis was 8.9 months on sunitinib, 
2 months less than that seen in the phase III trial, a difference 
that was attributed at least in part to the inclusion of patients 
with poorer risk profiles.
More recently combination therapy with bevacizumab 
and IFN has been evaluated in two randomized phase III trials 
in advanced RCC.38,39 In the first, 649 previously untreated 
Table 4 Results of an analysis of OS by individual baseline factors
Factor  OS P
HR 95% CI
Treatment (sunitinib vs iFN-α) 0.764 0.623–0.936 0.0096
eCOG PS (1 vs 1) 0.515 0.417–0.636 0.0001
Hemoglobin ( vs  LLN) 0.504 0.401–0.634 0.0001
Time from diagnosis to treatment ( vs  1 year) 0.574 0.461–0.715 0.0001
Corrected calcium ( vs  10 mg/dL) 0.466 0.327–0.664 0.0001
Alkaline phosphatase ( vs  ULN) 0.676 0.542–0.844 0.0005
Lactate dehydrogenase ( vs  1.5 × ULN) 0.500 0.337–0.742 0.0006
No of metastastic sites (1 vs  2) 0.664 0.503–0.876 0.0037
Abbreviations: CI, confidence interval; HR, hazard ratio; ULN, upper limits of normal; ECOG, Eastern Cooperative Oncology Group.
Reprinted from with permission. Motzer RJ, Hutson Te, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with etastatic 
renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.  Copyright © 2009 American Society of Clinical Oncology. All Rights Reserved. Cancer Management and Research 2010:2 129
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patients were randomized to receive either IFN-α-2a in 
combination with bevacizumab or placebo, and in the 
second 732 previously untreated patients were randomized 
to receive either bevacizumab plus IFN or IFN alone. The 
primary endpoint, overall survival, was not met in either 
trial. However, both studies reported significant improve-
ment in progression-free survival, from 5.2 months to 8.5 
months (P  0.0001),39 and from 5.2 months to 10.2 months 
(P = 0.0001).38
Only 10% of participants in the trials evaluating beva-
cizumab were classified as having poor prognostic features. 
When assessed by subgroup analysis, Escudier et al did not 
find a statistically significant improvement in progression-free 
survival in poor risk patients treated with bevacizumab plus 
IFN compared to placebo plus IFN (hazard ratio, 0.81, 95% 
CI, 0.46 to 1.42, P = 0.5083).38 In contrast, Rini et al did 
find a statistically significant improvement in progression-
free survival in patients with 3 or more MSKCC risk factors 
treated with bevacizumab plus IFN compared to IFN alone.39 
Rini et al also noted increased toxicities in the combination 
arm. Given the small numbers of participants classified as 
poor risk in these trials and the reliance on subgroup analysis, 
it is difficult to make definitive conclusions on the efficacy 
of bevacizumab in this subpopulation.
Treatment of metastatic RCC according 
to histologic subtype
Clear cell is the dominant histology in RCC and the focus of 
most clinical trials. While papillary and chromophobe tumors 
generally portend more favorable prognoses than clear cell 
histology, sarcomatoid tumors portend a worse prognosis. 
Patients identified in a phase II study of sunitinib comprised 
6% papillary and 2% sarcomatoid variants.42 Given the small 
numbers, subgroup analyses assessing sunitinib’s efficacy in 
these populations was not possible. A larger expanded access 
trial evaluating sunitinib in 4564 participants reported by 
Gore et al included 13% of patients with tumors displaying 
nonclear cell histology. Objective response rate in the overall 
study population was 17% with stable disease seen in 59%. 
Among those with nonclear cell histology the objective 
response rate was 11% with stable disease seen in 57%,43 
suggesting that while sunitinib may preferentially benefit 
those with clear cell histology, it is likely also active in those 
with tumors of nonclear cell histologies.
Management of sarcomatoid RCC is particularly chal-
lenging due to its typically aggressive behavior. While RCC 
is considered highly resistant to chemotherapy, gemcitabine-
containing regimens have shown some efficacy in patients 
with tumors containing sarcomatoid features with response 
rates of 5% to 17%.44
Nanus and colleagues reported on 18 patients, 56% with 
sarcomatoid advanced RCC, treated with combination doxo-
rubicin 50 mg/m2 and gemcitabine 1500 or 2000 mg/m2 every 
2 to 3 weeks with granulocyte-stimulating factor support.45 
Four of the 11 patients with sarcomatoid disease experienced 
a tumor response, and 2 additional patients experienced dis-
ease stability. The two patients in this study who experienced 
a complete remission both had sarcomatoid histology.
This combination was further studied in ECOG 8802, 
a phase II trial involving patients with tumors containing 
greater than 25% sarcomatoid features.46 Of 38 patients 
treated, there were 7 documented responses, 1 undocumented, 
and 9 patients with stable disease. Median overall survival 
was 8.8 months. Taken together, these studies suggest that 
gemcitabine-containing regimens may offer some benefit in 
treating patients with sarcomatoid variant RCC.
VEGF pathway inhibitors have been tested in combination 
with chemotherapy agents in other solid tumors with regimens 
containing bevacizumab showing efficacy in patients with 
breast, colon, lung and brain cancers.47–52 Michaelson et al stud-
ied the combination of sunitinib plus gemcitabine in 34 patients 
with advanced RCC and noted antitumor activity in 19.53 Of 
the 9 patients with poor risk or high grade RCC, 5 experi-
enced a partial response. Grade 4 adverse events, including 1 
myocardial infarction, 1 pulmonary embolism, and 2 patients 
with severe neutropenia, were observed in 4 patients. Results 
of this phase I study suggest that sunitinib in combination with 
gemcitabine may be active in patients with poor risk profiles 
and/or sarcomatoid histology, and a phase II study is underway 
to more clearly assess the efficacy of this combination.
Expanded access trials in RCC
Expanded access trials of sunitinib and sorafenib have 
included large number of patients, many of whom would 
be ineligible for participation in the more restrictive pivotal 
trials geared toward drug approval. Although these studies 
are not structured randomized controlled trials, they do pro-
vide valuable data regarding drug efficacy and tolerability 
in a patient population that is more reflective of community 
practice. Additionally expanded access trials are often large 
enough to provide efficacy data in subpopulations, such as 
those with poor prognostic features. Results, however, must 
be interpreted with caution given the study design. There 
are fewer requirements on study data parameters than in 
phase II and III clinical trials and thus data collected on 
response to therapy or toxicity may be incomplete.Cancer Management and Research 2010:2 130
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The safety and efficacy of sunitinib was studied in an 
expanded access trial reported by Gore and colleagues in 
2009.43 This study enrolled 4564 patients and included both 
previously treated and untreated participants. Only those who 
the investigator judged would not derive clinical benefit from 
sunitinib were excluded, and all participants had confirmed 
metastatic RCC, adequate organ function, and resolution of 
acute toxic effects of prior therapy. Tumor measurements and 
clinical assessments were not specified in the protocol but 
were performed according to local standards. Seven percent 
of study participants had brain metastases, 13% with ECOG 
performance status 2 or higher, 13% with nonclear cell RCC, 
32% were aged 65 years or older, and 9.8% met criteria for 
poor prognosis by MSKCC criteria.
Of the 3464 patients evaluated, the overall response rate 
was 17%. Among those with brain metastases the overall 
response rate was 12%, among those with ECOG perfor-
mance status 2 or more 9%, among those with nonclear cell 
RCC 11%, and among those aged 65 years or older 17%.43 
The incidence of grade 3 and 4 toxicities was comparable 
in the poor prognosis subgroups and overall population. 
Additionally, stable disease for at least 3 months was seen 
in 52% of patients with brain metastases, 52% of those with 
ECOG performance status 2 or more, 57% of those with 
tumors displaying nonclear cell histology, and 60% of those 
aged 65 years or older. Of the 373 patients meeting poor 
risk criteria by MSKCC criteria, median progression-free 
survival was 4.1 months (95% CI, 3.1 to 5.0) and median 
overall survival 5.3 months (95% CI, 4.6 to 6.4). This result 
is comparable to that seen in the phase III study compar-
ing sunitinib to IFN37,41 in which final analysis showed a 
median overall survival of 5.3 months in patients with poor 
risk features.41 Although sufficiently large randomized data 
is lacking, this expanded access study data suggest that 
sunitinib is a reasonable treatment option for patients with 
poor prognostic features. Patient survival, however, was still 
considerably shorter than in the general study population 
as a whole.
Brain metastases develop in about 10% of patients with 
metastatic RCC.54 Sunitinib has been shown to penetrate the 
central nervous systemic in animal studies.55 Seven percent of 
participants in the expanded access trial had brain metastases, 
and the toxicity profiles were similar among them as compared 
to the overall study population.43 However, it is notable that as of 
the data cutoff date, patients with brain metastases had received 
fewer treatment cycles than the overall study population. While 
antitumor activity of sunitinib and other VEGF inhibitors 
against brain metastases has been reported, a definitive role 
for VEGF-receptor inhibition in the treatment or prophylaxis 
of brain metastases has not been established.
An expanded access trial of sorafenib reported by 
Riechelmann et al enrolled 58 patients, including 14% poor 
risk according to the MSKCC prognostic index.56 Median 
progression-free survival was 7.5 months (95% CI, 5.4 to 
11.3 months). Among the 54 patients reported on, partial 
responses were seen in 20%, stable disease for 6 months 
in 28%, and progressive disease at 8 weeks in 18%. Although 
results were similar to those reported in the phase III trial of 
sorafenib,57 toxicities were greater with 64% of participants 
experiencing a grade 3 or 4 event.56 By univariate analysis, 
poor prognostic factors, including abnormal creatinine 
clearance, age, performance status, line of treatment, and 
presence of significant comorbidities, were not associated 
with increased likelihood of grade 3 or 4 adverse events.56 
These results imply that sorafenib may be effective in patients 
with poor risk features and that toxicities of treatment are 
not greater in this patient population.
The Advanced Renal Cell Carcinoma Sorafenib 
(ARCCS) trial in North America included 2488 partici-
pants.58 Inclusion criteria included adequate treatment of 
brain metastases and ECOG performance status 0 to 2, 
although waivers to participate were granted for patients 
with ECOG performance status 3 or 4. Exclusion criteria 
included treatment within the prior 4 weeks, life expectancy 
less than 2 months, uncontrolled hypertension, or renal fail-
ure requiring dialysis. Of 2488 enrolled, 1850 were evaluated 
for response. Unconfirmed results reported 17.5% partial 
response, and confirmed results showed 0.1% complete 
response, 3.6% partial response, 79.9% stable disease, and 
16.4% progressive disease. Specific information has yet to 
be reported on sorafenib activity in the subset of patients 
with poor risk features.
Future directions
Based on an improved understanding of RCC tumor biology, 
targeted therapies are being developed and outcomes are 
improving substantially for patients with advanced RCC. 
Clinical and pathologic criteria can be used to identify patients 
with poor prognosis. While patients with poor risk features 
have a more limited outcome, treatment with temsirolimus 
has led to meaningful improvements in overall survival in this 
population making this the standard of care. Definitive phase 
III trial data are lacking for the VEGF pathway inhibitors in 
this patient population. Nonetheless, current available data from 
subsets of phase III trials, retrospective analyses, and expanded 
access studies, suggest that patients with poor prognostic Cancer Management and Research 2010:2 131
Management of metastatic renal cell carcinoma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
features tolerate VEGF pathway blockade reasonably well and 
likely achieve some benefit relative to patients treated with 
interferon. Nonetheless progression-free survival and overall 
survival for this population remain poor on VEGF pathway 
inhibitors relative to those with more favorable disease prog-
nostic criteria. Therefore, more clinical investigation in this 
patient population is clearly necessary. Recent correlative 
science studies have begun to identify molecular features 
associated with poor prognosis RCC that may help to define 
novel treatment approaches specific for this patient popula-
tion. In the meantime, VEGF pathway inhibitors, including 
sunitunib, can be considered as alternatives to temsirolimus 
in untreated and treatment refractory patients with poor risk 
features.
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